Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Source: Globenewswire
Halneuron Phase 2b Study Update: Dogwood Therapeutics is on track to present interim data from its Phase 2b study of Halneuron, a treatment for chemotherapy-induced neuropathic pain, in Q4 2025, with low discontinuation rates indicating good tolerance among participants.
Company Overview and Future Plans: Dogwood Therapeutics focuses on developing non-opioid treatments for pain and fatigue-related disorders, with ongoing research into Halneuron's efficacy and plans for further clinical trials, including an antiviral program targeting conditions related to herpesvirus reactivation.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
